FA
MREO

Forefront Analytics’s Mereo BioPharma MREO Stock Holding History

Forefront Analytics’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-127,778
Closed -$42.2K – 39
2026
Q1 		$42.2K Buy
127,778
+96,010
+302% +$41.2K 0.04% 39
2025
Q4 		$13.2K Sell
31,768
-1,412
-4% -$2.69K 0.01% 43
2025
Q3 		$68.4K Buy
33,180
+14,042
+73% +$25.9K 0.07% 42
2025
Q2 		$51.9K Sell
19,138
-28,492
-60% -$68.8K 0.06% 41
2025
Q1 		$107K Buy
47,630
+12,877
+37% +$36.4K 0.12% 38
2024
Q4 		$122K Buy
34,753
+953
+3% +$3.74K 0.06% 56
2024
Q3 		$139K Sell
33,800
-2,431
-7% -$10.1K 0.07% 58
2024
Q2 		$130K Sell
36,231
-7,586
-17% -$24.6K 0.06% 61
2024
Q1 		$145K Buy
43,817
+7,693
+21% +$26K 0.07% 56
2023
Q4 		$83.4K Sell
36,124
-29,525
-45% -$56.5K 0.04% 62
2023
Q3 		$84.7K Sell
65,649
-17,100
-21% -$22.7K 0.05% 56
2023
Q2 		$109K Sell
82,749
-951
-1% -$1.1K 0.06% 55
2023
Q1 		$59.2K Buy
83,700
+10,200
+14% +$9.18K 0.03% 67
2022
Q4 		$55.1K Sell
73,500
-39,300
-35% -$32.3K 0.03% 67
2022
Q3 		$96K Buy
112,800
+36,950
+49% +$45.2K 0.05% 52
2022
Q2 		$83K Buy
+75,850
New +$58.8K 0.04% 53

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Forefront Analytics's MREO Position: Q2 2026 in Review

Forefront Analytics sold out of Mereo BioPharma (MREO) in Q2 2026, closing a stake of 127,778 shares — an estimated $42.2K sold.

Forefront Analytics first reported a position in MREO in Q2 2022 and held it in 16 quarters. The position peaked at $145K in Q1 2024. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

  • Forefront Analytics reported no remaining Mereo BioPharma position as of Q2 2026 after selling out during the quarter.
  • Forefront Analytics sold 127,778 Mereo BioPharma shares in Q2 2026, an estimated $42.2K.
  • Forefront Analytics first reported a position in Mereo BioPharma in Q2 2022 and held it in 16 quarters.
  • Forefront Analytics's Mereo BioPharma position peaked at $145K in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Forefront Analytics's 13F filing for Q2 2026, filed 13 Aug 2026.